PRGO logo

PERRIGO CO PLC

PRGONYSE
πŸ† #1955 by market capEarnings Nov 4US Equity
$15.00β–Ό $0.10 (βˆ’0.66%)
πŸŒ™ After hours$15.00β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track PRGO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.7%
7dβ–² 8.4%
14dβ–² 10.8%
30dβ–² 2.5%
ytdβ–² 7.8%
1yβ–Ό 32.6%
🏦Market Cap
$2.08B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-2.8%
Declining
πŸ“ŠGross Margin
33.3%
Moderate
πŸ’΅FCF Margin
4.2%
Moderate
βš–οΈP/S Ratio
0.5x
Cheap
Otter Score
92
Very Good

Trading Snapshot

Day Range
$14.94 – $15.23
52-Week Range
$9.23 – $22.65
Volume
$2.00B
Avg Volume
$1.35B
Shares Outstanding
138.4M
Next Earnings
Nov 13, 2026

Fundamentals Snapshot

Annual Revenue
$4.25B
Last Q Revenue
$1.02B
P/E Ratio
-1.2
P/S Ratio
0.5x
EPS (TTM)
$-12.47
Dividend Yield
7.68%
Dilution (1yr)
+0.7%

Why Investors Own PRGO

  • βœ“High-growth profile β€” revenue up +53.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 79% gross margin and 6% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PRGO logo

PERRIGO CO PLC

PRGO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4.3Bβ–Ό βˆ’2.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
35.1%β–Ό βˆ’0.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$343Mβ–² +204.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$145Mβ–Ό βˆ’40.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
138.5Mβ–² +0.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$3.4Bβ–Ό βˆ’$378M YoY
StockOtter Β· stockotter.space

About PERRIGO CO PLC

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
92/100

Analyst Ratings

β“˜
Consensus
Buy
10 analysts
Strong Buy2
Buy4
Hold4
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

Zacks Investment ResearchΒ·4d ago

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Defense WorldΒ·4d ago

Squarepoint Ops LLC Cuts Position in Perrigo Company plc $PRGO

Squarepoint Ops LLC reduced its stake in shares of Perrigo Company plc (NYSE: PRGO) by 95.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC)

Zacks Investment ResearchΒ·25d ago

Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

PRNewsWireΒ·Aug 27

Perrigo to Attend the Barclays Global Consumer Conference

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are schedul

Zacks Investment ResearchΒ·Aug 26

PRGO or NEOG: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?

Zacks Investment ResearchΒ·Aug 26

Should Value Investors Buy Perrigo (PRGO) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and